Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers StudyReport as inadecuate




Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study - Download this document for free, or read online. Document in PDF available to download.

Breast Cancer Research

, 19:52

First Online: 01 May 2017Received: 18 November 2016Accepted: 29 March 2017DOI: 10.1186-s13058-017-0840-7

Cite this article as: Clarke, C.A., Canchola, A.J., Moy, L.M. et al. Breast Cancer Res 2017 19: 52. doi:10.1186-s13058-017-0840-7

Abstract

BackgroundRegular users of aspirin may have reduced risk of breast cancer. Few studies have addressed whether risk reduction pertains to specific breast cancer subtypes defined jointly by hormone receptor estrogen and progesterone receptor and human epidermal growth factor receptor 2 HER2 expression. This study assessed the prospective risk of breast cancer overall and by subtype according to use of aspirin and other non-steroidal anti-inflammatory medications NSAIDs in a cohort of female public school professionals in California.

MethodsIn 1995 − 1996, participants in the California Teachers Study completed a baseline questionnaire on family history of cancer and other conditions, use of NSAIDs, menstrual and reproductive history, self-reported weight and height, living environment, diet, alcohol use, and physical activity. In 2005–2006, 57,164 participants provided some updated information, including use of NSAIDs and 1457 of these participants developed invasive breast cancer before January 2013. Multivariable Cox proportional hazards regression models provided hazard rate ratios HRR for the association between NSAID use and risk of invasive breast cancer as well as hormone receptor- and HER2-defined subtypes.

ResultsDeveloping breast cancer was associated inversely with taking three or more tablets of low-dose aspirin per week 23% of participants. Among women reporting this exposure, the HRR was 0.84 95% confidence interval CI 0.72–0.98 compared to those not taking NSAIDs and this was particularly evident in women with the hormone receptor-positive-HER2-negative subtype HRR = 0.80, 95% CI 0.66–0.96. Use of three or more tablets of -other- NSAIDs was marginally associated with lower risk of breast cancer HRR = 0.79, 95% CI 0.62–1.00. Other associations with NSAIDs were generally null.

ConclusionOur observation of reduced risk of breast cancer, among participants who took three or more tablets of low-dose aspirin weekly, is consistent with other reports looking at aspirin without differentiation by dose. This is the first report to suggest that the reduction in risk occurs for low-dose aspirin and not for regular-dose aspirin and only among women with the hormone receptor-positive-HER2-negative subtype. This preliminary study builds on previous knowledge and further supports the need for formal cancer chemoprevention studies of low-dose aspirin.

KeywordsAspirin NSAIDs Breast cancer Hormone receptor HER2 Subtype Epidemiology 



Author: Christina A. Clarke - Alison J. Canchola - Lisa M. Moy - Susan L. Neuhausen - Nadia T. Chung - James V. LaceyJr - Lesl

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents